NCT07590635 eCardiacRehab - a Hybrid Patient-Centered eHealth Programme
| NCT ID | NCT07590635 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Haukeland University Hospital |
| Condition | Comorbidities and Coexisting Conditions |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2026-05-21 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2026-05-21 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The overall aim of eCardiacRehab trial is to meet rehabilitation needs of patients with coronary artery disease (CAD) regardless of their access to traditional place-based rehabilitation by developing and evaluating the efficacy and cost effectiveness of an interdisciplinary and comprehensive home-based hybrid programme. eCardiacRehab address patient- and system level challenges to increase access to cardiac rehabilitation (CR). We give particular attention to older patients, women, and those with comorbidities or mental health challenges. The vision of the hybrid home-based eCardiacRehab programme is to make CR available to all. eCardiacRehab is a prospective, multicentre randomized open-label blinded end point evaluation (PROBE) trial. The primary endpoint is a hierarchical composite endpoint using a win-ratio framework combining cardiovascular (CV) death, unplanned contacts to the Emergency Department (ED) for observation or admission (\>24 hours) for CV disease, and quality of life. Inclusion criteria are adult Scandinavian speaking patients (≥ 18 years) who have a Norwegian national identification number, with CAD treated with Percutaneous Coronary Intervention (PCI), are living at home, and have internet available to them and providing signed informed consent. Exclusion criteria are patients with severe aortic stenosis, severe arrhythmias, expected lifetime less than one year as determined by study personnel, otherwise clinically unstable, not fully revascularized, awaits PCI or coronary artery bypass graft operation (CABG) or inability to comply with the study protocol due to any physical disability, somatic disease, cognitive impairment or mental health challenges as determined by study personnel.
Eligibility Criteria
Inclusion Criteria: * Adult Norwegian (or Scandinavian) speaking patients (≥ 18 years) who have a Norwegian national identification number * With coronary artery disease after percutaneous coronary intervention * Living at home * Have internet available * Provide signed informed consent Exclusion Criteria: * Patients with cognitive impairment that may interfere with the ability to comply with the study protocol * Severe aortic stenosis * Severe arrhythmias * Expected lifetime less than one year as determined by study personnel * Otherwise clinically unstable * Not fully revascularized * Awaits percutaneous coronary intervention or coronary artery bypass graft surgery * Inability to comply with the study protocol due to any physical disability, somatic disease, or mental problems as determined by study personnel
Contact & Investigator
Tone M Norekvål, PhD
PRINCIPAL INVESTIGATOR
Haukeland University Hospital
Frequently Asked Questions
Who can join the NCT07590635 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Comorbidities and Coexisting Conditions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07590635 currently recruiting?
Yes, NCT07590635 is actively recruiting participants. Contact the research team at trond.roed.pettersen@helse-bergen.no for enrollment information.
Where is the NCT07590635 trial being conducted?
This trial is being conducted at Bergen, Norway.
Who is sponsoring the NCT07590635 clinical trial?
NCT07590635 is sponsored by Haukeland University Hospital. The principal investigator is Tone M Norekvål, PhD at Haukeland University Hospital. The trial plans to enroll 1,000 participants.